Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Shteinberg

Showing results (71-80 of 143) with videos related to

Pageof 15
Sort By:
ERJ Open Research|January 28, 2025
Treatment effects of CFTR modulators on people with cystic fibrosis carrying the Q359K/T360K variantKarin Yaacoby-Bianu, Moshe Heching, Mordechai R Kramer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 12, 2023
A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancyJennifer L Taylor-Cousar, Rachel Janney, Peter G Middleton, et al.
European Journal of Endocrinology|August 29, 2003
Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexesJean De Schepper, Johan Schiettecatte, Brigitte Velkeniers, et al.
Annals of the American Thoracic Society|July 25, 2024
Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis with Mildly Decreased and Normal Lung Function: A Real-Life Observational StudyKarin Yaacoby-Bianu, Adi Dagan, Malena Cohen-Cymberknoh, et al.
Lung|September 16, 2015
Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis OutcomesMichal Shteinberg, Joseph Rivlin, Michal Gur, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 13, 2022
Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutationsGalit Livnat, Adi Dagan, Moshe Heching, et al.
Lung|September 10, 2014
Asymptomatic carriage of Pneumocystis jirovecii and cytomegalovirus in lungs of immunocompetent patientsMichal Shteinberg, Pninit Shaked-Mishan, Amalia Kinarti, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 12, 2020
'Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020Mona Al Langawi, Cass Byrnes, Jane C Davies, et al.
Cancer Immunology, Immunotherapy : CII|May 23, 2018
Novel non-invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profilesYochai Adir, Shoval Tirman, Shirley Abramovitch, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 6, 2024
Treatment effects of elexacaftor/tezacaftor/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variantMoshe Heching, Michal Shteinberg, Inbal Golan-Tripto, et al.
Pageof 15

Showing results (71-80 of 143) with videos related to

Sort By:
Pageof 15
ERJ Open Research|January 28, 2025
Treatment effects of CFTR modulators on people with cystic fibrosis carrying the Q359K/T360K variantKarin Yaacoby-Bianu, Moshe Heching, Mordechai R Kramer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 12, 2023
A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancyJennifer L Taylor-Cousar, Rachel Janney, Peter G Middleton, et al.
European Journal of Endocrinology|August 29, 2003
Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexesJean De Schepper, Johan Schiettecatte, Brigitte Velkeniers, et al.
Annals of the American Thoracic Society|July 25, 2024
Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis with Mildly Decreased and Normal Lung Function: A Real-Life Observational StudyKarin Yaacoby-Bianu, Adi Dagan, Malena Cohen-Cymberknoh, et al.
Lung|September 16, 2015
Lack of Association Between Haptoglobin Phenotype and Cystic Fibrosis OutcomesMichal Shteinberg, Joseph Rivlin, Michal Gur, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 13, 2022
Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutationsGalit Livnat, Adi Dagan, Moshe Heching, et al.
Lung|September 10, 2014
Asymptomatic carriage of Pneumocystis jirovecii and cytomegalovirus in lungs of immunocompetent patientsMichal Shteinberg, Pninit Shaked-Mishan, Amalia Kinarti, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 12, 2020
'Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020Mona Al Langawi, Cass Byrnes, Jane C Davies, et al.
Cancer Immunology, Immunotherapy : CII|May 23, 2018
Novel non-invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profilesYochai Adir, Shoval Tirman, Shirley Abramovitch, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 6, 2024
Treatment effects of elexacaftor/tezacaftor/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variantMoshe Heching, Michal Shteinberg, Inbal Golan-Tripto, et al.
Pageof 15